Canada · Delayed Price · Currency is CAD Cardiol Therapeutics Statistics
Total Valuation
TSX:CRDL has a market cap or net worth of CAD 315.42 million. The enterprise value is 289.45 million.
| Market Cap | 315.42M |
| Enterprise Value | 289.45M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSX:CRDL has 116.82 million shares outstanding. The number of shares has increased by 28.88% in one year.
| Current Share Class | 116.82M |
| Shares Outstanding | 116.82M |
| Shares Change (YoY) | +28.88% |
| Shares Change (QoQ) | +5.46% |
| Owned by Insiders (%) | 2.95% |
| Owned by Institutions (%) | 11.97% |
| Float | 92.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 13.13 |
| P/TBV Ratio | 13.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.55, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.55 |
| Quick Ratio | 5.01 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -190.18% and return on invested capital (ROIC) is -124.20%.
| Return on Equity (ROE) | -190.18% |
| Return on Assets (ROA) | -90.92% |
| Return on Invested Capital (ROIC) | -124.20% |
| Return on Capital Employed (ROCE) | -148.81% |
| Weighted Average Cost of Capital (WACC) | 6.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.89M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +73.08% in the last 52 weeks. The beta is 0.47, so TSX:CRDL's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +73.08% |
| 50-Day Moving Average | 1.90 |
| 200-Day Moving Average | 1.64 |
| Relative Strength Index (RSI) | 66.23 |
| Average Volume (20 Days) | 262,271 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.86M |
| Pretax Income | -34.08M |
| Net Income | -34.08M |
| EBITDA | -35.85M |
| EBIT | -35.86M |
| Earnings Per Share (EPS) | -0.34 |
Balance Sheet
The company has 26.08 million in cash and 106,998 in debt, with a net cash position of 25.97 million or 0.22 per share.
| Cash & Cash Equivalents | 26.08M |
| Total Debt | 106,998 |
| Net Cash | 25.97M |
| Net Cash Per Share | 0.22 |
| Equity (Book Value) | 24.03M |
| Book Value Per Share | 0.21 |
| Working Capital | 23.96M |
Cash Flow
In the last 12 months, operating cash flow was -24.05 million and capital expenditures -56,720, giving a free cash flow of -24.10 million.
| Operating Cash Flow | -24.05M |
| Capital Expenditures | -56,720 |
| Depreciation & Amortization | 9,196 |
| Net Borrowing | -55,376 |
| Free Cash Flow | -24.10M |
| FCF Per Share | -0.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSX:CRDL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.88% |
| Shareholder Yield | -28.88% |
| Earnings Yield | -10.80% |
| FCF Yield | -7.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for TSX:CRDL is 6.00, which is 122.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 6.00 |
| Price Target Difference | 122.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |